1. Doctor, I know that you have been
anxious to have a new product in your
treatment arsenal. Today, I am excited to
share with you new IQUIX® (Ievofloxacin
ophthalmic solution) 1.5%, a newer­
generation fluoroquinolone that
delivers powerful sustained levels of
concentration, both above and below
the ocular surface. New IQUIX® 1.5%
takes concentrat,ion to a new level.
For , h wfth pllyskJilIJs.
re~t4l11ve <Be only. MJ'. til be
®
I
(Ievofloxacin aphtha mic
FORTRAIN G ,pu POSES ONLY.
or fOR DETAIUNG. DO NOT
so utquot;on) 1.5%
DUPLICATE OR DISTRIBUTE.
a ew
Ta tion
Concan Ll::=iVe=

2. Doctor, you should feel confident that
IQUIX® delivers sustained levels of
concentration above and below the
ocular surface.
New IQUIX 1.5% is the only newer
fluoroquinolone approved for treatment
of corneal ulcers, and deli,vers high
ApPIIquot;ll)led 0
sustained concentrations where your
High Btnined, Concentratio
patients may need it most. It provides
'a~13l;' ~llS1alns i~
111 /'1 concenlli ions
R3p:aly ac tearsquot;
rapid penetration in tears that is
Penelrates human co.-neal Issue ood llq1.:eous 11U1nor to con:enlrations thai exceed MIG.
sustained over time. IQUIX® also achieves
valll~s of commo ocular pathogens'
high concentrations in human corneal
High Concentr; • n and ODv 89
tissue and aqueous humor that exceed
Broad c(werage of gram-l1l3g3tlve and gram-poo; i~e pathogens, Including P aerlJgillosB,
the MIC90 values of common ocullar
S. marcescens. S. awe ,S, epiderm/dis, and S. pr.-elJm(lniae'
pathogens. IQUIXc:; has broad coverage of
Qc;ular TRU.s . s~etll data documents h/g susceptibility of key
(2QOO.2007}' gram-negative pathogens, including
Dual mechanism of action $imilar 0 galifloxacin and moxifioxac nt Pseudomonas aeruginosa and Serratia
marcescens, as well as gram-positive
B.tion
II-·Yoltel'l!l't:ad 'Co
pathogens, including Staph epidermidis.
do heiJal ce!ls
Low cylotoXJly to bolh human comool
and keratocyles'
The high susceptibility of key ocular
Pw.~ervative--free. form~iatlo~l
near neutral pH pathogens is further documented by the
Ocular TR.U.S.T surveillance data. But
equally important, IQUIX® is well
tolerated. It is preservative-free with a
near neutra I pH, and is less cytotoxic tha n
other newer FQs.
Pro e: Now that you know how new
IQUIXill 1.5% measures up to the other
new r fQ . at you use r., your practice,
..........-.......,..--­
will yo u pr scri e IQUI XQI wne n you nBed
,.,
a potent nuoroquinolon with sustained
con centrations ov r ti m@?
FORTiRAJNI G PURPOSES 0 LV: OT FOR DETAtlING. ®
DO, 0 DUPLICATE OR D STRIBU
o
II • 1l.C.. II~ t~lIar'a ':'~ I)s:cro .s';mhQ Co lid, Tokyc. J,mol1 ..,. _.
(Ievofloxacin ophthalmquot;c
Ov~ 1.:trrlpeJe. t '11. nj §mtlll1·
Urllltnil«:l Lv $.:I
.2. ­
(I..'Lio1J1ttTl,;:::! t·yVrST/ooJ(.{JN ~m-=f1uU LLC. J~k~onville. -/orjl'lquot;
:So
rttilW!:i!W lrad~ .. oIVI~rJ.KOr-.:
VISTAKO 14 f'llarmacl!u cals, LLof
OJ
SO utio ) .5%,
r,·quot;'ar acllllicals, LLC 200i' 2707)0-014
Allllq quot;IS reserved 10107
1/ S AKU'-
Ta e -one nation a Ne evel
0

3. In-fused with
~sed with, R'E MOD U 1 I N~'
(treprostin11 50dium) Injectio
.
When initial therapy loses momentum, think REMODULlN@
'5t a nlv Prostacyclin for Bo nfusio
JLlNf/ll delivers the power of continuously infused prostacyclin with:
a:::.
packs necessary
half-life
•
ODU
rized pump options
(treprostinil sodium) Injection
)L1N delivers results
led hemodynamics
;hed symptoms associated with exercise in NYHA Class II-IV patients Joanne
REMODULIN patient
ted deterioration In those requiring transition from Flolan®
JLlN has flexible dosing
to titrate to effect
t8 hours (IV) or 72 hours (SC) between reservoir changes
nt Safety Information: Chronic intravenous infusions of
JLlN are delivered using an Indwelling central venous catheter.
e is associated with the risk of blood stream infections (BSI)
IS, which may be fatal.
Iportant Safety Information on page 17.
II prescribing informiltio~ in pocket.
liled
erapeutics
J •